Breaking News Instant updates and real-time market news.

CARA

Cara Therapeutics

$21.54

-0.23 (-1.06%)

07:06
07/09/19
07/09
07:06
07/09/19
07:06

Cara Therapeutics initiates Phase 2 trial of Oral KORSUVA

Cara Therapeutics announced the initiation of a Phase 2 trial of Oral KORSUVA for the treatment of pruritus in patients with atopic dermatitis. AD is one of the most common chronic inflammatory diseases with prevalence rates of up to 5% in adults and approximately 25% in children. The Phase 2 randomized, double-blind, placebo-controlled study is designed to evaluate the efficacy and safety of Oral KORSUVA for moderate-to-severe pruritus in approximately 240 adult subjects with AD. Subjects will be randomized to three tablet strengths of Oral KORSUVA: 0.25 mg, 0.5 mg and 1 mg taken twice daily vs. placebo for 12 weeks followed by a 4-week active extension phase.The primary efficacy endpoint is the change from baseline in the weekly mean of the daily 24-hour Itch Numeric Rating Scale score at Week 12 of the treatment period. Secondary endpoints include change from baseline in itch-related quality of life scores at the end of Week 12 as assessed by the total Skindex-10 and 5-D itch scales, as well as the proportion of patients achieving an improvement from baseline of greater than or equal to4 points with respect to the weekly mean of the daily 24-hour I-NRS score at Week 12.

CARA Cara Therapeutics
$21.54

-0.23 (-1.06%)

05/29/19
NEED
05/29/19
NO CHANGE
Target $35
NEED
Strong Buy
Cara Therapeutics price target raised to $35 from $28 at Needham
Needham analyst Alan Carr raised his price target for Cara Therapeutics to $35 from $28 after the company reported that the Korsuva Phase 3 KALM-1 trial met all primary and secondary endpoints. Statistically significant and clinically meaningful effects were observed across pruritus and quality of life assessments, Carr tells investors in a research note. The analyst assumes the FDA will recommend Cara submit a new drug application after the "nearly identical" KALM-2 trial is completed in the second half of 2019. He keeps a Buy rating on the shares.
05/29/19
HCWC
05/29/19
NO CHANGE
Target $28
HCWC
Buy
Cara Therapeutics price target raised to $28 from $26 at H.C. Wainwright
H.C. Wainwright analyst Oren Livnat raised his price target for Cara Therapeutics to $28 from $26 saying this morning's "robust" KALM-1 results bolster his "bullish" expectations. KALM-1 delivered, with highly statistically significant results versus placebo on all primary and secondary endpoints, Livnat tells investors in a research note. The analyst adds that the general consistency from Phase 2b supports his confidence in likely success of the global KALM-2 study for which he expects topline data by Q4. Livnat maintains an "already high" 80% probability of success on IV Korsuva and keeps a Buy rating on Cara Therapeutics.
05/29/19
JEFF
05/29/19
NO CHANGE
Target $34
JEFF
Buy
Jefferies boosts Cara Therapeutics target to $34 on 'home run' data
Jefferies analyst Chris Howerton raised his price target for Cara Therapeutics to $34 from $25 saying he views the KALM-1 results as "very positive." The efficacy is a "home run" scenario, and there was no surprise in the adverse events profile, Howerton tells investors in a research note. The analyst now has increased confidence on Cara's entire pipeline. He keeps a Buy rating on the shares. Cara Therapeutics in late morning trading is up 11%, or $2.00, to $19.98.
07/01/19
PIPR
07/01/19
NO CHANGE
Target $35
PIPR
Overweight
Piper reiterates Overweight on Cara Therapeutics after nephrologist survey
Piper Jaffray analyst David Amsellem polled 25 nephrologists who manage a significant number of hemodialysis patients to gauge perceptions of the intravenous form of Cara Therapeutics' Korsuva in pruritus associated with chronic kidney disease. There is good familiarity with the body of data in the dialysis setting, most respondents perceive an unmet medical need, and most respondents have favorable impressions of Cara's data, Amsellem tells investors in a research note. The analyst says the survey reinforced our view that IV Korsuva will emerge as a valued anti-pruritic in hemodialysis patients. He views the U.S. sales opportunity "well north" of $400M-$500M and reiterates an Overweight rating on Cara Therapeutics with a $35 price target.

TODAY'S FREE FLY STORIES

TAP

Molson Coors

$54.37

0.08 (0.15%)

18:06
07/18/19
07/18
18:06
07/18/19
18:06
Hot Stocks
Molson Coors raises quarterly dividend to 57c from 41c per share »

Molson Coors declared a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

MSFT

Microsoft

$136.29

0.06 (0.04%)

18:04
07/18/19
07/18
18:04
07/18/19
18:04
Hot Stocks
Breaking Hot Stocks news story on Microsoft »

Microsoft up over 2%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 03

    Aug

  • 06

    Aug

  • 08

    Aug

BAS

Basic Energy

$1.81

-0.1 (-5.24%)

18:02
07/18/19
07/18
18:02
07/18/19
18:02
Hot Stocks
Basic Energy announces record setting lateral completion in Permian Basin »

Basic Energy Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 13

    Nov

MSFT

Microsoft

$136.29

0.06 (0.04%)

18:02
07/18/19
07/18
18:02
07/18/19
18:02
Hot Stocks
Microsoft CFO continues to expect double digit revenue growth in FY20 »

Sees FY20 operating…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 03

    Aug

  • 06

    Aug

  • 08

    Aug

QTRH

Quarterhill

$1.23

(0.00%)

18:02
07/18/19
07/18
18:02
07/18/19
18:02
Hot Stocks
WiLAN unit acquires patent portfolio from Vidiator »

Wi-LAN announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$136.29

0.06 (0.04%)

18:00
07/18/19
07/18
18:00
07/18/19
18:00
Earnings
Microsoft sees total Q1 revenue at implied $31.7B-$32.4B, consensus $32.0B »

By segment: Sees Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 03

    Aug

  • 06

    Aug

  • 08

    Aug

RRGB

Red Robin

$30.58

0.32 (1.06%)

18:00
07/18/19
07/18
18:00
07/18/19
18:00
Hot Stocks
Red Robin up 17% after confirming $40.00 per share offer from Vintage Capital »

In after-hours trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$33.09

-0.17 (-0.51%)

17:54
07/18/19
07/18
17:54
07/18/19
17:54
Periodicals
AT&T mulls sale of Puerto Rican business to pay down debt, Bloomberg says »

AT&T, which is eyeing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 30

    Jul

  • 08

    Aug

RRGB

Red Robin

$30.58

0.32 (1.06%)

17:53
07/18/19
07/18
17:53
07/18/19
17:53
Hot Stocks
Red Robin confirms $40.00 per share cash buyout proposal from Vintage Capital »

Red Robin confirmed it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$136.29

0.06 (0.04%)

17:50
07/18/19
07/18
17:50
07/18/19
17:50
Hot Stocks
Microsoft CFO: Q4 another quarter of double-digit top and bottom line growth »

Says commercial bookings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 03

    Aug

  • 06

    Aug

  • 08

    Aug

HBIO

Harvard Bioscience

$1.78

0.03 (1.71%)

17:46
07/18/19
07/18
17:46
07/18/19
17:46
Hot Stocks
Harvard Bioscience names Michael Rossi CFO »

Harvard Bioscience has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$136.29

0.06 (0.04%)

17:43
07/18/19
07/18
17:43
07/18/19
17:43
Hot Stocks
Microsoft CEO seeing growing momentum across every layer of its stack »

Says LinkedIn saw record…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 03

    Aug

  • 06

    Aug

  • 08

    Aug

ISRG

Intuitive Surgical

$536.44

13.25 (2.53%)

17:38
07/18/19
07/18
17:38
07/18/19
17:38
Hot Stocks
Intuitive Surgical falls after Q2 report, despite earnings beat »

Shares of Intuitive are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 26

    Aug

  • 09

    Sep

GLD

SPDR Gold Shares

$136.44

1.85 (1.37%)

17:33
07/18/19
07/18
17:33
07/18/19
17:33
Hot Stocks
SPDR Gold Shares holdings rise to 814.62MT from 803.18MT »

This is the highest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAL

Western Alliance

$44.45

0.74 (1.69%)

17:29
07/18/19
07/18
17:29
07/18/19
17:29
Earnings
Western Alliance reports Q2 EPS 1.19, consensus $1.16 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 06

    Aug

ENB

Enbridge

$36.29

0.17 (0.47%)

17:22
07/18/19
07/18
17:22
07/18/19
17:22
Initiation
Enbridge initiated at Goldman Sachs »

Enbridge initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

SEAS

SeaWorld

$33.81

0.38 (1.14%)

17:21
07/18/19
07/18
17:21
07/18/19
17:21
Periodicals
Travel company Virgin Holidays will end selling tickets to SeaWorld, Sun says »

According to the Sun, …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

IEP

Icahn Enterprises

$75.06

-0.14 (-0.19%)

17:20
07/18/19
07/18
17:20
07/18/19
17:20
Syndicate
Breaking Syndicate news story on Icahn Enterprises »

Icahn Enterprises files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RICK

RCI Hospitality

$16.80

0.08 (0.48%)

17:13
07/18/19
07/18
17:13
07/18/19
17:13
Hot Stocks
RCI Hospitality auditor BDO resigns, company files Nasdaq compliance plan »

RCI Hospitality announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BEDU

Bright Scholar

$9.60

-0.06 (-0.62%)

17:03
07/18/19
07/18
17:03
07/18/19
17:03
Earnings
Bright Scholar reports Q3 EPS 16c, two estimates 21c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

ISRG

Intuitive Surgical

$536.44

13.25 (2.53%)

17:03
07/18/19
07/18
17:03
07/18/19
17:03
Hot Stocks
Intuitive Surgical refines FY19 procedure growth view to 16%-17% from 15%-17% »

Still sees FY19 tax rate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 26

    Aug

  • 09

    Sep

CUB

Cubic

$66.59

-0.37 (-0.55%)

17:01
07/18/19
07/18
17:01
07/18/19
17:01
Hot Stocks
Cubic receives extension on simulation services contract in Australia »

Cubic Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLRO

ClearOne

$2.27

(0.00%)

16:52
07/18/19
07/18
16:52
07/18/19
16:52
Hot Stocks
Shure files patent infringement suit against ClearOne »

Shure announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ISRG

Intuitive Surgical

$536.44

13.25 (2.53%)

16:50
07/18/19
07/18
16:50
07/18/19
16:50
Hot Stocks
Intuitive Surgical says 74% of systems placed in Q2 were da Vinci XIs »

Says team has done a nice…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 26

    Aug

  • 09

    Sep

ETN

Eaton

$79.03

-0.36 (-0.45%)

16:49
07/18/19
07/18
16:49
07/18/19
16:49
Hot Stocks
Eaton acquires Innovative Switchgear Solutions »

Eaton announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.